John S. Montalbano - 06 Nov 2023 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Director
Signature: Tryn Stimart, attorney-in-fact
Issuer symbol: ABCL
Transactions as of: 06 Nov 2023
Net transactions value: +$137,400
Form type: 4
Filing time: 08 Nov 2023, 15:29:53 UTC
Previous filing: 05 Dec 2022
Next filing: 24 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Purchase	$92,800	+20,000	+36%	$4.64	76,000	06 Nov 2023	Direct
transaction	ABCL	Common Shares	Purchase	$44,600	+10,000	+13%	$4.46	86,000	08 Nov 2023	Direct	F1
holding	ABCL	Common Shares						5,000	06 Nov 2023	By Spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $4.45 to $4.46. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $4.45 to $4.46. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.